Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mark Keegan

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
The Lancet. Neurology|July 23, 2011
Natalizumab for multiple sclerosis: a complicated treatmentB Mark Keegan
Seminars in Neurology|May 28, 2013
Therapeutic decision making in a new drug era in multiple sclerosisB Mark Keegan
Seminars in Neurology|May 28, 2013
Current and emerging therapies for multiple sclerosisB Mark Keegan
Multiple Sclerosis and Related Disorders|March 7, 2025
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?Samar Ikram, B Mark Keegan
Mayo Clinic Proceedings|January 8, 2004
61-year-old woman with shortness of breath after surgeryNima Mowzoon, B Mark Keegan
Archives of Neurology|July 11, 2012
Cutting-edge questions about CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids)B Mark Keegan, Sean J Pittock
Mayo Clinic Proceedings|June 20, 2014
In reply--Sensitivity of [18F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathyB Mark Keegan, Eoin P Flanagan
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|September 7, 2007
Severe, reversible dysphagia from chloroquine and hydroxychloroquine myopathyFarrah J Mateen, B Mark Keegan
Ocular Immunology and Inflammation|June 30, 2018
Reply to: "Crowell et al. Idiopathic Central Nervous System Inflammatory Disease in the Setting of HLA-B27 Uveitis"W Oliver Tobin, B Mark Keegan
Annual Review of Medicine|January 31, 2002
Multiple sclerosisB Mark Keegan, John H Noseworthy
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
The Lancet. Neurology|July 23, 2011
Natalizumab for multiple sclerosis: a complicated treatmentB Mark Keegan
Seminars in Neurology|May 28, 2013
Therapeutic decision making in a new drug era in multiple sclerosisB Mark Keegan
Seminars in Neurology|May 28, 2013
Current and emerging therapies for multiple sclerosisB Mark Keegan
Multiple Sclerosis and Related Disorders|March 7, 2025
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?Samar Ikram, B Mark Keegan
Mayo Clinic Proceedings|January 8, 2004
61-year-old woman with shortness of breath after surgeryNima Mowzoon, B Mark Keegan
Archives of Neurology|July 11, 2012
Cutting-edge questions about CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids)B Mark Keegan, Sean J Pittock
Mayo Clinic Proceedings|June 20, 2014
In reply--Sensitivity of [18F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathyB Mark Keegan, Eoin P Flanagan
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|September 7, 2007
Severe, reversible dysphagia from chloroquine and hydroxychloroquine myopathyFarrah J Mateen, B Mark Keegan
Ocular Immunology and Inflammation|June 30, 2018
Reply to: "Crowell et al. Idiopathic Central Nervous System Inflammatory Disease in the Setting of HLA-B27 Uveitis"W Oliver Tobin, B Mark Keegan
Annual Review of Medicine|January 31, 2002
Multiple sclerosisB Mark Keegan, John H Noseworthy
Pageof 12